Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.…
Prelude Therapeutics Incorporated (PRLD) Reports Q3 Loss, Beats Revenue Estimates
Prelude Therapeutics (NASDAQ: PRLD) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 79 employees.
The shares were at 3.230 USD on 20 November 2026, up 139.3% over 52 weeks. Its 52-week range is 1.173 USD to 6.830 USD: the price is 52.7% below the high and 175.4% above the low.
Its market capitalisation is 258.63M USD.
Prelude Therapeutics reports return on equity of -145.0%, an operating margin of -280.2% and revenue down 13.1% year over year.
It holds more cash than debt, a net cash position of 122.44M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 5 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 8.800 USD is 172.4% above the current price. The next earnings report is expected on 9 March 2027.